Abstract
Objective: To formulate and evaluate budesonide-pectin beads using novel assembly with a peristaltic pump.Methods: The prepared budesonide-pectin dispersion was added to calcium chloride solution with the help of assembly. Provided at least 2 h for hardening and dried at 60 °C for 3 h. Assembly was assembled with the use of a peristaltic pump, polymeric solution reservoir, hose, needle, magnetic stirrer, gelling bath. One side of hose was dipped in pectin solution container and another side was passed through the peristaltic pump and connected to the needle. Peristaltic pump produced pumping of pectin solution through the hose. Needles with variable diameters are available. The gelling bath was kept on magnetic stirrer to keep prepared beads in motion, which helped to provide new surface and sufficient reaction time and helped to avoid agglomeration. There were 10 different batches with different process parameters prepared. Production yield, the diameter of beads, swelling index, and in vitro budesonide dissolution in phosphate buffer pH 7.4 after 5 h was determined.Results: There was a significant difference between selection of process parameter among the batches (p = 0.049, q = 6.11). As nozzle diameter was increased, percentage yield was decreased (p = 0.0038, q>5.98). However, if hardening time was decreased percentage release was increased (p = 0.0361, q>5.98).Conclusion: The novel assembly for bead generation had developed a uniform, spherical shaped, and smooth surfaced beads.
Highlights
Budesonide is a glucocorticoid [1]
In case of rotating disc atomizer, the polymer solution is fed onto rotating disc whereas, in case of rotating nozzle atomizer, polymer solutions flow through the atomizer having multiple nozzles
The assembly of co-axial air stream method has two connections, one is attached to the top of the nozzle for polymer solution and another is attached to the tip of nozzle to supply air stream
Summary
Budesonide is a glucocorticoid [1]. It undergoes significant first-pass degradation (80–90%) and is rapidly and extensively biotransformed into 6-β-hydroxy budesonide and 16-α-hydroxy prednisolone, which has no or negligible (
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
